The size of the Smart Inhalers Market in the Asia Pacific was worth USD 14.67 million in 2020 and estimated to be growing at a CAGR of 75.23% to reach USD178.11 million by 2025.
The growth of the APAC smart inhalers market is primarily due to an increasing elderly population, an increased prevalence of chronic obstructive pulmonary disease and asthma, and increased medical awareness.
The growth of the smart inhaler market is due to increased air pollution, and the burden on healthcare services due to the increased number of cases of COPD and asthma. Besides, more smart inhalers are being used to properly manage COPD and asthma, further driving the market growth. The rapid development of urbanization and an increase in the number of people with respiratory diseases are increasing throughout the Asia-Pacific region.
Some of the other factors that have led to an increase in the number of cases of asthma and COPD throughout the Asia-Pacific region are increased air pollution levels and increased smoking habits. An increasing number of patients with asthma and chronic obstructive pulmonary disease and technological advances in developing better smart inhalers and systems is to present growth opportunities for the market. Also, in developing regions with large populations and the potential of untapped markets is expected to provide ample opportunities for trends in the Asia-Pacific smart inhalers market.
The dearth of skilled persons is a major challenging factor in the APAC Smart Inhalers Market. Fluctuations in the availability of raw materials used to manufacture smart inhalers are limiting the growth of the market.
This research report segmented and sub-segmented into the following categories:
Regionally, the Asia-Pacific region is anticipated to have the fastest-growing rate due to the high investments by the government organizations and private companies in the medical industry, growth in the aging population, and emerging economies like China and India.
India and China are the two major countries contributing to the highest shares of the market. Increasing the economy steadily from the past few years is ascribed to bolster the demand of the market in these countries. Besides, growing awareness among people towards the availability of various products is also greatly influencing the demand of the smart inhalers market. Rising need to launch innovative products in favor of the end-users is extensively boosting up the growth rate of this market. Japan is next to these countries in holding dominant shares of the market with a growing number of respiratory diseases. The emergence of advanced technology and also the rising scale of research centers in the medical sector are promoting the demand of the market. Australia and the Rest of the Asia Pacific are deemed to have a steady pace during the forecast period. Rise in the prevalence to provide better healthcare infrastructure and facilities to the patients is lucrative to setup growth opportunities for the market in these countries.
The Top companies leading in the APAC Smart Inhalers Market profiled in the report are Vectura Group plc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Adherium Limited, Cohero Health, LLC, Propeller Health, GlaxoSmithKline plc and OPKO Health, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Nebulizers
5.1.3 Inhalers
5.1.3.1 Metered Dose Inhalers (MDIs)
5.1.3.2 Dry Powder Inhalers (DPIs)
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Disorder
5.2.1 Introduction
5.2.2 Chronic Obstructive Pulmonary Disease (COPD)
5.2.3 Asthma
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Disorder
5.2.6 Market Attractiveness Analysis, By Disorder
5.2.7 Market Share Analysis, By Disorder
5.3 End-user
5.3.1 Introduction
5.3.2 Patients
5.3.3 R&D
5.3.4 Others
5.3.5 Y-o-Y Growth Analysis, By End-user
5.3.6 Market Attractiveness Analysis, By End-user
5.3.7 Market Share Analysis, By End-user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Disorder
6.1.3.4 By End-user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Disorder
6.1.4.4 By End-user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Disorder
6.1.5.4 By End-user
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Vectura Group plc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Teva Pharmaceutical Industries Ltd.,
8.3 GlaxoSmithKline plc
8.4 Boehringer Ingelheim GmbH
8.5 AstraZeneca plc,
8.6 Adherium Limited
8.7 Cohero Health, LLC,
8.8 Propeller Health
8.9 GlaxoSmithKline plc
8.10 OPKO Health, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
